A PROSPECTIVE STUDY OF CARDIOVASCULAR DISEASE IN ESRD

ESRD 中心血管疾病的前瞻性研究

• 批准号: 6730560
• 负责人: MICHAEL J KLAG
• 金额: $ 12.47万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-01 至 2005-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6730560
• 关键词: African American; blood lipid; blood pressure; cardiovascular disorder; cardiovascular disorder epidemiology; cholesterol; chronic renal failure; clinical research; dialysis therapy; disease /disorder proneness /risk; genetic susceptibility; homocysteine; human subject; linkage mapping; longitudinal human study; vitamin B complex

DESCRIPTION (taken from the application) We are in the midst of an epidemic of end stage renal disease (ESRD). Treated ESRD has increased exponentially at an annual rate of 8% since 1973 when the U.S. ESRD treatment registry was initiated. Although it preserves life, treated ESRD is associated with poor quality of life, considerable morbidity, and high mortality. The leading cause of death in treated ESRD patients is cardiovascular disease. The Principal Investigator is a leader in the epidemiology and prevention of renal disease who has an outstanding track record in patient-oriented research and mentorship. He has assembled and mentored a team of superb young investigators who are seeking to understand better the reasons for the increased risk of cardiovascular disease in patients with treated ESRD and less severe forms of renal disease. Mentorship is accomplished through a rigorous program of training in epidemiologic methods and intensive involvement in ongoing, federally-funded research projects. Tuition costs are covered by NIH sponsored training grants from NIDDK and NHLBI. The current proposal requests funds to increase the Principal Investigator's ability to mentor trainees and junior faculty by decreasing his substantial administrative commitment. The research projects described in this proposal are built on the foundation of the CHOICE Cohort Study, a national prospective study of over 1,000 incident cases of ESRD. A DNA and serum bank has been established at a central laboratory. Current research project conducted by trainees who will be mentored by the Principal Investigator as part of the current proposal include: 1. The role of emerging risk factors (Lpa, homocysteine, B vitamin, fibrinogen levels) in risk of CVD ESRD patients; 2. Identification of genes that increase risk of progression to ESRD; 3. Risk factors for vascular access failure. This information will lay the groundwork to prevent CVD in ESRD patients by providing the information needed for clinical trials. The Principal Investigator has a long history of successful mentoring in renal disease research. The proposed award will allow him to continue training the next generation of renal disease epidemiologists.

描述(取自应用程序) 我们正处于终末期肾病(ESRD)的流行之中。已治疗 自1973年以来，ESRD以每年8%的指数速度增长，当时 启动了美国ESRD治疗登记。虽然它保住了生命，治疗了 ESRD与生活质量差、相当高的发病率和较高的 死亡率。经治疗的终末期肾病患者的主要死亡原因是 心血管疾病。首席调查员是 谁在肾脏疾病流行病学和预防方面有突出成绩 在以病人为中心的研究和指导方面有记录。他已经集结并 指导了一支优秀的年轻调查人员团队，他们试图了解 更好地解释患者心血管疾病风险增加的原因 治疗终末期肾病和不太严重的肾脏疾病。导师制就是 通过严格的流行病学方法培训计划完成 以及深入参与正在进行的、由联邦政府资助的研究项目。 学费由NIH赞助的NIDDK和 NHLBI。目前的建议要求资金增加本金 调查员指导实习生和初级教员的能力 实质性的行政承诺。 本建议中所述的研究项目是建立在 选择队列研究，一项针对1000多起事件的全国性前瞻性研究 终末期肾病5例。DNA和血清库已经在一个中心建立起来 实验室。由将接受指导的学员进行的当前研究项目 作为当前提案的一部分，首席调查员的建议包括： 1.新出现的危险因素(LPA、同型半胱氨酸、维生素B、纤维蛋白原)的作用 心血管疾病终末期肾病患者的风险水平)； 2.确定增加进展为终末期肾病风险的基因； 3.血管通路失败的危险因素。 这一信息将为预防终末期肾病患者的心血管疾病奠定基础 提供临床试验所需的信息。《校长》 研究人员在肾脏疾病的成功指导方面有很长的历史 研究。拟议的奖励将允许他在下一年继续训练 一代肾脏疾病流行病学家。